You Position: Home > Paper
新型无氟喹诺酮——苹果酸奈诺沙星
( views:250, downloads:614 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Tuberculosis and Respiratory Diseases
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1001-0939.2018.04.017
- Key Word:
- No keyword available
Abstract： 苹果酸奈诺沙星(Nemonoxacin,简称奈诺沙星)是近年来由我国台湾TaiGen生物技术公司研发的一种新型6位不含氟的C8-甲氧基结构喹诺酮类新型抗菌药物[1],2012年浙江医药股份有限公司获得该产品的生产和销售权,2016年5月由中国食品药物监督管理局(CFDA)批准上市,用于治疗轻、中度成人社区获得性肺炎(community-acquired pneumonia,CAP).这是自2015年CFDA发布“关于开展药物临床试验数据自查核查工作的公告”以来,在我国唯一批准上市的1.1类抗菌药物,被国家卫生计生委列为“十二五”计划的国家新药创制专项[2].
- [1]朱德妹,吴培澄,胡付品,等.奈诺沙星体外抗菌作用研究[J].2015,(2).
- [2]Laing NM,King CR,Adam HJ.In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.[J].2009,53(11).
- [3]Yu,J.,Wu,X.,Shi,Y.,etc.Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses[J].2012,32(7).
- [4]Mosharov EV.,Vitvitsky VM.,Ataullakhanov FI.,etc.A substrate switch: A new mode of regulation in the methionine metabolic pathway[J].2000,204(4).
- [5]Tan CK,Lai CC,Liao CH.Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis.[J].2009,64(2).
- [6]A. Arjona..Nemonoxacin[J].2009,34(3).